Edaravone

Summary

Edaravone (CHEMBL290916) is an approved small-molecule radical scavenger (ATC N07XX14); indicated across 7 conditions including amyotrophic lateral sclerosis and stroke disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N07XX14
• Indications: 7 conditions
• Clinical trials: 38
• Chemistry: 174.2 Da · C10H10N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL290916
Name	Edaravone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4021
ChEBI	CHEBI:31530
ATC	N07XX14
Molecular formula	C10H10N2O
Molecular weight	174.2
InChIKey	QELUYTUMUWHWMC-UHFFFAOYSA-N

SMILES: CC1=NN(C(=O)C1)C2=CC=CC=C2

IUPAC name: 5-methyl-2-phenyl-4H-pyrazol-3-one

ChEBI definition: A pyrazolone that is 2,4-dihydro-3H-pyrazol-3-one which is substituted at positions 2 and 5 by phenyl and methyl groups, respectively.

Pharmacological roles (ChEBI): radical scavenger, antioxidant.

Also known as: Antipyrine related compound a, C.i. developer 1, Colorex pmp, Developer z, Edaravona, Edaravone, Jarocol pmp, MCI-186, Norphenazone, NSC-12, NSC-26139, NSC-2629

Patent coverage: 4,014 distinct patent families (10,153 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, Histone-lysine N-methyltransferase 2A, Protein RecA, Replicative DNA helicase DnaB, Thyrotropin receptor, Menin/Histone-lysine N-methyltransferase MLL.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 34 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15917	8.8	Potency	1.6	nM	CHEMBL_ACT_4671095
SMN1	6.15	Potency	707.9	nM	CHEMBL_ACT_3873993
KDM4E	5.95	Potency	1122	nM	CHEMBL_ACT_3704859
ALDH1A1	5.6	Potency	2512	nM	CHEMBL_ACT_4179878
P9WMR3	5.56	AC50	2753	nM	CHEMBL_ACT_6592142
MAPT	5.55	Potency	2818	nM	CHEMBL_ACT_4009520
P9WHJ3	5.53	EC50	2950	nM	CHEMBL_ACT_6750351
P9WMR3	5.49	AC50	3243	nM	CHEMBL_ACT_7253474
KDM4E	5.45	Potency	3548	nM	CHEMBL_ACT_3709156
MAPT	5.35	Potency	4467	nM	CHEMBL_ACT_4036383
ALDH1A1	5.3	Potency	5012	nM	CHEMBL_ACT_4142235
ALDH1A1	5	Potency	10000	nM	CHEMBL_ACT_4131994
ALDH1A1	5	Potency	10000	nM	CHEMBL_ACT_4168458

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
amyotrophic lateral sclerosis	4	MONDO:0004976	MONDO:0004976
stroke disorder	2	MONDO:0005098	EFO:0000712
brain injury	2	MONDO:0043510	MONDO:0043510
intracerebral hemorrhage	2	MONDO:0013792	EFO:0005669
liver disorder	1	MONDO:0005154	EFO:0001421
kidney disorder	1	MONDO:0005240	EFO:0003086

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 38.

Phase distribution

Phase	Trials
PHASE2	10
PHASE1	8
PHASE4	7
PHASE3	7
Not specified	5
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06645522	PHASE4	NOT_YET_RECRUITING	Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke
NCT07119021	PHASE4	RECRUITING	Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
NCT07454473	PHASE4	RECRUITING	Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study
NCT00153946	PHASE4	COMPLETED	Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke
NCT00200356	PHASE4	COMPLETED	Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
NCT00265239	PHASE4	COMPLETED	Pilot Study of Edaravone to Treat Acute Myocardial Infarction
NCT06248242	PHASE4	UNKNOWN	Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol
NCT00330681	PHASE3	COMPLETED	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT00415519	PHASE3	COMPLETED	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
NCT00424463	PHASE3	COMPLETED	Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01492686	PHASE3	COMPLETED	Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
NCT02430350	PHASE3	COMPLETED	Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
NCT03272802	PHASE2/PHASE3	UNKNOWN	Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT05249920	PHASE3	COMPLETED	Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)
NCT05885919	PHASE3	UNKNOWN	Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
NCT00821821	PHASE2	COMPLETED	Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
NCT01865201	PHASE2	COMPLETED	Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis
NCT01929096	PHASE2	COMPLETED	Compound Edaravone Injection for Acute Ischemic Stroke
NCT03968042	PHASE2	UNKNOWN	Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury
NCT04391361	PHASE2	UNKNOWN	The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS
NCT04667637	PHASE2	COMPLETED	Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol
NCT04714177	PHASE2	UNKNOWN	Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage
NCT04817527	PHASE2	UNKNOWN	Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows
NCT04984577	PHASE2	SUSPENDED	Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
NCT05035953	PHASE2	UNKNOWN	Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
NCT01518231	PHASE1	UNKNOWN	Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke
NCT03289208	PHASE1	COMPLETED	Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
NCT03289234	PHASE1	COMPLETED	Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03664544	PHASE1	COMPLETED	PK Study in Subjects With Severe Hepatic Impairment
NCT04029090	PHASE1	COMPLETED	A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects
NCT04218513	PHASE1	COMPLETED	Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection
NCT04493281	PHASE1	COMPLETED	Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
NCT06107205	PHASE1	COMPLETED	Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects
NCT05540262	Not specified	RECRUITING	Edaravone in the Treatment of Optic Neuritis
NCT01894334	Not specified	UNKNOWN	Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection
NCT02644915	Not specified	UNKNOWN	Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients
NCT05121883	Not specified	UNKNOWN	Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke
NCT05644223	Not specified	UNKNOWN	Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).